VERA - VERA

에 대한 최신 뉴스 Vera Therapeutics (NASDAQ:VERA) 주식

Vera Therapeutics

VERAMARK TECHS INC

Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.

Equities

Macro Economic Events

Macro Notification

Market Summary

News

Sector ETFs

Politics

Treasuries

Economics

Markets

ETFs

COST

INTC

NFLX

NVDA

TSLA

VERA

미국 주식시장은 경제 모멘텀 둔화가 미국 기업들의 실적 전망에 영향을 미칠 수 있다는 투자자들의 우려로 이번 주에 5주 연속 상승세를 마감했다. 미국 경제는 1분기에 연율 1.3% 성장해 이전 추정치 1.6%보다 하향 조정되었다.

이번 주 시장 동향: 월가 5주 연속 상승 마감, 경제 성장 속도 감소, 트럼프의 유죄 평결 등

Biotech

Fintech news covering the emerging Financial Technology services sector

Fintech

Large Cap

Mid Cap

Health Care

Small Cap

Tech

$BTC

AVGO

CVNA

MSTR

SLNO

엔비디아(NASDAQ:NVDA)는 지난 1년간 수익률 순위에서 나스닥 100 지수 1위를 차지하며 눈에 띄는 기술 주식이었다.
이 칩 제조업의 거인은 인공지능(AI) 개발을 위한 칩에 대한 급증하는 수요로, 지난 2023년 5월 말 이후 무려 186%나 급등했다.

엔비디아는 1년 전 대비 186% 상승했지만, 다음의 7개 주식은 이보다 두 배 이상의 수익 기록

Vera Therapeutics, Inc. - Class A Common Stock

Vera Therapeutics Inc

Vera Bradley Inc

Veracyte Inc

Veradigm Inc

VERALLIA,COURBEVOIE by VERALLIA, COURBEVOIE

Verallia

Veralto Corp

VERANO HLDGS CORP by Verano Holdings Corp.

Verano Holdings Corp

Verasity

Verastem Inc

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the<a href="https://www.benzinga.com/topic/rsi"> RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Viking Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>)</h3>
<ul>
<li>On Jan. 17, HC Wainwright &amp; Co. analyst Joseph Pantginis reiterated Viking Therapeutics with a Buy and maintained a $102 price target.. The company' stock fell around 22% over the past month and has a <a href="https://www.benzinga.com/quote/VKTX">52-week low of $20.83</a>.</li>
<li>RSI Value: 28.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>VKTX Price Action: Shares of Viking Therapeutics gained 0.7% to close at $32.87 on Tuesday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012225&amp;t=be2bearmibe3na1">latest VKTX news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012225&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="901" height="830" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035334/image-138.png" alt="" class="wp-image-744179" style="width:593px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035334/image-138.png 901w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035334/image-138-300x276.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035334/image-138-768x707.png 768w" sizes="(max-width: 901px) 100vw, 901px" /></a></figure>
<h3 class="wp-block-heading">Radnet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDNT#NASDAQ">RDNT</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>On Jan. 15, Jefferies analyst Brian Tanquilut maintained RadNet with a Buy rating and lowered the price target from $100 to $80. The company's stock fell around 11% over the past five days and <a href="https://www.benzinga.com/quote/RDNT">has a 52-week low</a> of $35.16.</li>
<li>RSI Value: 25.2</li>
<li>RDNT Price Action: Shares of Radnet gained 0.6% to close at $60.19 on Tuesday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012225&amp;t=be2bearmibe3na1">trend in RDNT stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012225&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="920" height="843" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035427/image-139.png" alt="" class="wp-image-744183" style="width:539px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035427/image-139.png 920w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035427/image-139-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035427/image-139-768x704.png 768w" sizes="(max-width: 920px) 100vw, 920px" /></a></figure>
<h3 class="wp-block-heading">Vera Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>)</h3>
<ul>
<li>On Jan. 13, Vera Therapeutics secured an exclusive license from Stanford University for VT-109, a next-generation fusion protein targeting BAFF and APRIL. VT-109 offers broad therapeutic potential for B cell-mediated diseases, reinforcing Vera's position in B cell modulation. The company's stock fell around 20% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/VERA">low of $15.46.</a></li>
<li>RSI Value: 27.2</li>
<li>VERA Price Action: Shares of Vera Therapeutics gained 1% to close at $33.70 on Tuesday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012225&amp;t=be2bearmibe3na1">VERA shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012225&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="902" height="845" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035516/image-140.png" alt="" class="wp-image-744188" style="width:583px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035516/image-140.png 902w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035516/image-140-300x281.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22035516/image-140-768x719.png 768w" sizes="(max-width: 902px) 100vw, 902px" /></a></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43096091/jim-cramer-this-tech-stock-is-a-buy-louisiana-pacific-has-been-a-great-stock">Jim Cramer: This Tech Stock Is A Buy, Louisiana-Pacific Has Been A &#8216;Great Stock&#8217;</a></li>
</ul>

Long Ideas

Pre-Market Outlook

Trading Ideas

RDNT

VKTX

Top 3 Health Care Stocks That Could Blast Off This Quarter

Vera Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) shares are trading lower by 7.3% to $34.31 Monday afternoon. The company announced an <a href="https://www.benzinga.com/pressreleases/25/01/g42940821/vera-therapeutics-acquires-global-rights-to-novel-next-generation-dual-baffapril-inhibitor">exclusive license agreement</a> with Stanford University for VT-109.
What To Know: Vera Therapeutics has secured an exclusive license from Stanford University for VT-109, a next-generation fusion protein targeting BAFF and APRIL. VT-109 offers broad therapeutic potential for B cell-mediated diseases, reinforcing Vera&#8217;s position in B cell modulation.
CEO Marshall Fordyce highlighted the company&#8217;s commitment to leveraging its expertise to advance the molecule&#8217;s potential and improve outcomes for patients with severe autoimmune diseases. 
Under the agreement, Vera gains development and marketing rights for VT-109 in exchange for undisclosed upfront and milestone payments.
Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/25/01/42953940/tuesdays-producer-inflation-report-could-stoke-market-volatility-as-fed-path-remains-unclear">Tuesday&#8217;s Producer Inflation Report Could Stoke Market Volatility As Fed Path Remains Unclear</a>
<h2 class="wp-block-heading">How To Buy VERA Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Vera Therapeutics&#8217;s case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, VERA has a 52-week high of $51.61 and a 52-week low of $14.20.

What's Going On With Vera Therapeutics Stock?

WIIM

Vera Therapeutics shares are trading lower. The company announced an exclusive license agreement with Stanford University for VT-109.

Contracts

General

Vera Therapeutics Announced An Exclusive License Agreement With Stanford University For Fusion Protein Targeting BAFF And APRIL, Known As VT-109, With Therapeutic Potential Across The Spectrum Of B Cell-mediated Diseases For Undisclosed Upfront And Milestone Payments

Wells Fargo analyst Mohit Bansal initiates coverage on Vera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) with a Overweight rating and announces Price Target of $70.

Price Target

Initiation

Analyst Ratings

Wells Fargo Initiates Coverage On Vera Therapeutics with Overweight Rating, Announces Price Target of $70

Wedbush analyst Laura Chico maintains Vera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) with a Neutral and raises the price target from $30 to $38.

Wedbush Maintains Neutral on Vera Therapeutics, Raises Price Target to $38

Vera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) reported quarterly losses of $(0.85) per share which missed the analyst consensus estimate of $(0.64) by 32.81 percent. This is a 88.89 percent decrease over losses of $(0.45) per share from the same period last year.

Earnings

Earnings Misses

Vera Therapeutics Q3 EPS $(0.85) Misses $(0.64) Estimate

JP Morgan analyst Anupam Rama maintains Vera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) with a Overweight and raises the price target from $72 to $75.

JP Morgan Maintains Overweight on Vera Therapeutics, Raises Price Target to $75

Reported Earlier, Vera Therapeutics Prices $300M Public Offering Of 7,142,858 Class A Common Shares At $42/Share

Vera Therapeutics shares are trading lower after the company announced plans to commence a public offering to issue and sell $300 million of its Class A common stock.

In connection with the proposed offering, Vera expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of Class A common stock sold in the public offering.&nbsp;

Offerings

Vera Therapeutics Plans To Commence Public Offering To Issue And Sell $300M Of Shares Of Its Class A Common Stock

Guggenheim analyst Vamil Divan maintains Vera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) with a Buy and raises the price target from $56 to $64.

Guggenheim Maintains Buy on Vera Therapeutics, Raises Price Target to $64

On Saturday, Vera Therapeutics Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) released data from its ORIGIN Phase 2b trial of atacicept in immunoglobulin A nephropathy (IgAN), which showed stabilized kidney function through 96 weeks <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/g41562227/vera-therapeutics-announces-96-week-egfr-stabilization-in-origin-phase-2b-study-of-atacicept-in-ig" rel="noreferrer noopener">of long-term follow-up</a>.
These data were presented in a late-breaking oral presentation at the American Society of Nephrology Kidney Week 2024 and published in a&nbsp;manuscript&nbsp;in the&nbsp;Journal of the American Society of Nephrology.
Over 96 weeks, participants treated with atacicept demonstrated a -66% reduction in galactose-deficient IgA1 (Gd-IgA1), resolution of hematuria in 75% of participants, a -52% reduction in proteinuria, and a mean annualized estimated glomerular filtration rate (eGFR) slope of -0.6 mL/min/1.73m2/year.
The cumulative generally favorable safety profile of atacicept remained consistent with that observed during the randomized period, with a 90% completion rate of atacicept treatment.
The company says these data support the potential for atacicept to offer long-term, comprehensive IgAN disease modification and provide further confidence in the ongoing pivotal Phase 3 ORIGIN 3 trial of atacicept in IgAN.
The company plans to initiate an ORIGIN Extend study in the fourth quarter of 2024, which will provide ORIGIN participants with extended access to atacicept before its commercial availability.
The ORIGIN 3 trial is on track to announce topline results in the second quarter of 2025, with planned FDA marketing application submission later in the year.
Earlier this year, Vera Therapeutics revealed 72-week data from the open-label extension (OLE) period of its Phase 2b ORIGIN clinical trial of atacicept in participants with IgA nephropathy (IgAN).&nbsp;
Data from the OLE showed the consistent and sustained reductions of serum galactose-deficient IgA1 (Gd-lgA1), hematuria, and urine protein to creatinine ratio (UPCR), as well as the stability of eGFR over 72 weeks&nbsp;in <a target="_blank" href="https://www.benzinga.com/general/biotech/24/01/36807507/whats-going-on-with-vera-therapeutics-stock-today" rel="noreferrer noopener">participants with IgAN</a>.&nbsp;
Price Action: VERA stock is up 12.2% at $46.12 at last check Monday.
Image via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41571498/gryphon-digital-restructures-18-million-debt-with-lender-anchorage-grants-it-board-seat" target="_blank" rel="noreferrer noopener">Gryphon Digital Restructures $18 Million Debt With Lender Anchorage, Grants It Board Seat</a></li>
</ul>

Movers

Vera Therapeutics' Atacicept Shows Sustained, Substantial Improvement In Kidney Function For Patients At Almost Two Years

U.S. stocks were higher, with the Dow Jones index gaining around 200 points on Monday.
Shares of PROCEPT BioRobotics Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCT#NASDAQ">PRCT</a>) rose sharply during Monday's session after the company reported better-than-expected third-quarter financial results and raised its <a href="https://www.benzinga.com/quote/PRCT/earnings">FY24 revenue guidance</a>.
PROCEPT BioRobotics shares jumped 25% to $85.87 on Monday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Monte Rosa Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLUE#NASDAQ">GLUE</a>) shares jumped 60.5% to $7.85 after the company announced a global license agreement with Novartis to advance VAV1 MGDs. The company will receive a $150 million upfront payment and is eligible for additional milestone payments.</li>
<li>EyePoint Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYPT#NASDAQ">EYPT</a>) gained 33.6% to $12.69 after the company showed early trial data for DURAVYU for diabetic macular edema and announced improving vision and anatomy.</li>
<li>Revance Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) shares gained 25.5% to $5.89 after the company announced it entered into the sixth amendment to its exclusive distribution agreement with Teoxane.</li>
<li>ImmunityBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>) gained 19.5% to $6.36.</li>
<li>Trump Media &amp; Technology Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) rose 15.3% to $44.91. The stock may be moving amid possible volatility as traders evaluate his chance of winning the 2024 presidential election.</li>
<li>Prothena Corporation plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) surged 15.3% to $17.66.</li>
<li>Serve Robotics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERV#NASDAQ">SERV</a>) gained 13.8% to $11.09. Ladenburg Thalmann analyst Glenn Mattson initiated coverage on Serve Robotics with a Buy rating and announced a price target of $16.</li>
<li>Vera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) rose 12.1% to $46.05 after the company reported 96-week eGFR stabilization on Saturday for its Phase 2b study of IgAN patients with Atacicept.</li>
<li>MINISO Group Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNSO#NASDAQ">MNSO</a>) gained 10.3% to $19.21.</li>
<li>TeraWulf Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WULF#NASDAQ">WULF</a>) rose 10.2% to $7.03.</li>
<li>WeRide Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WRD#NASDAQ">WRD</a>) gained 9% to $18.03.</li>
<li>Newell Brands Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWL#NASDAQ">NWL</a>) rose 8.3% to $9.45. Canaccord Genuity analyst Brian McNamara maintained Newell Brands with a Buy and raised the price target from $12 to $13.</li>
<li>MicroStrategy Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) gained 7% to $251.00 amid a rise in Bitcoin.</li>
<li>MARA Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARA#NASDAQ">MARA</a>) rose 6.3% to $18.14 amid a rise in Bitcoin.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41570746/top-3-real-estate-stocks-that-may-surge-in-q4">Top 3 Real Estate Stocks That May Surge In Q4</a></li>
</ul>

Intraday Update

EYPT

GLUE

IBRX

MARA

MNSO

PRCT

PRTA

RVNC

SERV

WULF

PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday

Vera Therapeutics shares are trading higher after the company reported 96-week eGFR stabilization on Saturday for its Phase 2b study of IgAN patients with Atacicept.

<ul>
<li>Long-term improvements observed in the quartet of findings defining disease modification supports atacicept&#39;s potential to prevent kidney failure in patients with IgAN;</li>
<li>Long-term results from the ORIGIN Phase 2b study were simultaneously published in the&nbsp;Journal of the American Society of Nephrology;</li>
<li>Company will host an investor call and webcast on Monday October 28 at 8:00 AM ET</li>
</ul>

Reported Saturday, Vera Therapeutics Reveals 96-Week eGFR Stabilization In IgAN Patients with Atacicept: ORIGIN Phase 2b Study Findings Presented At ASN Kidney Week

Scotiabank analyst Greg Harrison initiates coverage on Vera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) with a Sector Outperform rating and announces Price Target of $60.

Scotiabank Initiates Coverage On Vera Therapeutics with Sector Outperform Rating, Announces Price Target of $60

Cantor Fitzgerald analyst Pete Stavropoulos reiterates Vera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) with a Overweight and maintains $107 price target.

Reiteration

Cantor Fitzgerald Reiterates Overweight on Vera Therapeutics, Maintains $107 Price Target

Vera Therapeutics To Present Long-term Results From Origin Phase 2B Clinical Trial Of Atacicept For Treatment Of IgAN

This program is expected to build on the positive data reported to date from the ongoing ORIGIN Phase 2b and 3 clinical program developing atacicept to treat patients with IgAN, by extending into a broader population of IgAN and other autoimmune kidney indications.

Vera Therapeutics Reports Expansion Of Its Development Pipeline For Its Lead Asset, Atacicept

JPMorgan updates its U.S. Analyst Focus List – Adds TPR, ALRM, REG

Wall Street Lunch: Holiday-Shortened Week Starts Positively

TD Cowen analyst Ritu Baral maintained a Buy rating on Vera Therapeutics (VERA – Research Report) today. The company's shares closed yesterday at $...

Vera Therapeutics (VERA) Receives a Buy from TD Cowen

Vera Therapeutics: Strong Data In IgAN, But We May Be Too Late

Vera Therapeutics (VERA) announced an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BA...

Vera Therapeutics acquires global rights to next-gen dual BAFF/APRIL inhibitor

An announcement from Vera Therapeutics ( ($VERA) ) is now available. Vera Therapeutics announced an updated corporate presentation at the J.P. Morg...

Vera Therapeutics Highlights Atacicept Progress at Conference

Rami Katkhuda, an analyst from LifeSci Capital, maintained the Buy rating on Vera Therapeutics (VERA – Research Report). The associated price targe...

Vera Therapeutics: Strategic Licensing and Promising Clinical Data Justify Buy Rating

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below are Strong Buys. Each stock received a new B...

3 Best Stocks to Buy Now, 1/17/2025, According to Top Analysts

TD Cowen analyst Ritu Baral maintained a Buy rating on Vera Therapeutics (VERA – Research Report) today and set a price target of $60.00. The compa...

TD Cowen Sticks to Its Buy Rating for Vera Therapeutics (VERA)

Analyst Farzin Haque of Jefferies maintained a Buy rating on Vera Therapeutics (VERA – Research Report), with a price target of $58.00. Farzin Haqu...

Vera Therapeutics: Promising Clinical Progress and Strategic Positioning Drive Buy Rating

ABBV

AGCO

ALRM

AMZN

ARMK

ASND

BACRP

BPMC

BRBR

CYBR

DAWN

DCGO

DELL

DKNG

EWTX

GWRE

ISRG

KLAC

KVUE

LEGN

MNDY

MSFT

NTRA

PODD

PTCT

REGCO

REGCP

ROIV

RVMD

RZLV

SCHW

SIRI

SNDX

SPGI

SWTX

TFII

TMUS

TRGP

TVTX

ULTA

VICI

VRTX

XENE

Press Releases

Vera Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

Vera Therapeutics to Participate at Upcoming Investor Conferences

Vera Therapeutics Partners with University of Michigan on the NEPTUNE Match Project and PIONEER Study

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Management

Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer

Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Vera Therapeutics Acquires Global Rights to Novel, Next Generation Dual BAFF/APRIL Inhibitor

Comments

Vera Therapeutics

뉴스

에 대한 최신 뉴스 Vera Therapeutics (NASDAQ:VERA) 주식

토요일, 6월 01, 2024

수요일, 5월 29, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌